AbbVie Inc. (ABBV)
| Market Cap | 389.72B |
| Revenue (ttm) | 58.33B |
| Net Income (ttm) | 3.72B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.10 |
| PE Ratio | 105.04 |
| Forward PE | 16.70 |
| Dividend | $6.56 (2.97%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 4,206,211 |
| Open | 220.63 |
| Previous Close | 218.54 |
| Day's Range | 217.67 - 221.48 |
| 52-Week Range | 163.81 - 225.16 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 225.09 (+2.03%) |
| Earnings Date | Oct 29, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $225.09, which is an increase of 2.03% from the latest price.
News
AbbVie For Healthy Dividend Growth
AbbVie is rated a strong buy for its strong dividend growth, robust fundamentals, and proven track record as a Dividend King. ABBV offers a compelling mix of a 3% yield and nearly 7% annual historical...
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials rei...
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds...
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
New AA (Allergan Aesthetics) Signature™ multimodal treatment approach to be presented at AMWC Dubai following successful launch in 25 countries so far this year. Experts to explore the paradigm shift ...
These Dividend Stocks Have Big Yields and Are Beating the Odds
Income is lagging growth this year. But companies like Seagate, Newmont, Tapestry and CVS offer the best of both worlds: solid dividend yields and strong stock performance.
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
SKINVIVE ® to launch in 35 additional markets worldwide from September taking the total to 57 international launches in 2025. Research highlights 94% of people want to improve facial skin quality1*, w...
Calls of the Day: Netflix, Disney, Walmart and AbbVie
The Investment Committee debate the latest Calls of the Day.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.
The company is dealing with declining sales of its former cash-cow drug Humira.
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, accord...
AbbVie in Settlement With Generic Drugmakers on Rinvoq
The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie Inc. ABBV stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food an...
AbbVie: What's Happening With ABBV Stock?
AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Exec...
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Building on the brand's 20-year legacy and real-world experience, the original BOTOX® Cosmetic continues to be the most researched and requested product of its kind.1,2 BOTOX® Cosmetic is trusted by a...
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
The Investment Committee discuss the latest Calls of the Day.
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill. , Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EP...
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NORTH CHICAGO, Ill. , Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025.